What is KLRS (KLRS) stock price today?

KLRS (KLRS) is currently trading at $3.92, down 2.97% today.

What is KLRS P/E ratio?

KLRS's P/E ratio is -2.86. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is KLRS return on equity (ROE)?

KLRS's return on equity (ROE) is -66.60%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is KLRS's market cap?

KLRS has a market capitalization of $85.56M.

NASDAQ · Biotechnology

KLRS (KLRS) Stock

$3.92 -2.97% NASDAQ: KLRS Healthcare

Valuation

Metric	Value
Price	$3.92
Market Cap	$85.56M
P/E Ratio	-2.86
P/B Ratio	1.52
P/S Ratio	0.00
EPS (TTM)	$-1.52
52-Week High	$11.88
52-Week Low	$2.14
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-66.60%
ROA	-27.97%
ROCE	-58.23%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	11.90

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-170.0M	$-14.0M	$-13.0M	$-55.0M	$-46.0M
Net Profit	$-172.0M	$-15.0M	$-15.0M	$-59.0M	$-43.0M
EPS	$-63.00	$-50.62	$-42.09	$-11.73	$-2.85
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$287.0M	$4.0M	$3.0M	$119.0M	$122.0M
Total Liabilities	$61.0M	$34.0M	$48.0M	$5.0M	$43.0M
Cash	$202.0M	$3.0M	$3.0M	$118.0M	$98.0M
Borrowings	$30.0M	$3.0M	$0	$0	$1.0M

Latest News

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board Insider Monkey · Jul 14, 2026 Kalaris Appoints Laurie Keating to Board of Directors GlobeNewswire · Jul 6, 2026 Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling GlobeNewswire · Jun 23, 2026 TD Cowen Initiates Kalaris Therapeutics at Buy MT Newswires · Jun 15, 2026 Kalaris to Present at Clinical Trials at the Summit 2026 GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-106.0M	$-10.0M	$-14.0M	$-68.0M	$-43.0M
Investing Cash Flow	$186.0M	$0	$0	$95.0M	$-20.0M
Financing Cash Flow	$0	$0	$2.0M	$0	$102.0M
Net Cash Flow	$79.0M	$3.0M	$0	$28.0M	$-20.0M
Free Cash Flow	$-106.0M	$-10.0M	$-14.0M	$-68.0M	$-43.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-10.97
EV / EBITDA	—
FCF Yield	-57.55%
Quick Ratio	12.14
Interest Coverage	-46.00
Return 1Y	94.58%
Return 3Y	-94.20%
Return 5Y	-98.85%

Ownership

Insiders Held8.81%

Institutions Held77.88%

Institutions Float Held85.40%

Institutional Holder	Shares	Report Date
Samsara BioCapital, LLC	12,948,081	2026-03-31
RTW Investments LP	1,300,000	2026-03-31
Paradigm Biocapital Advisors LP	700,000	2026-03-31
Alyeska Investment Group, L.p.	572,687	2026-03-31
Siren, L.L.C.	435,798	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARTV	$11.28	-0.18%	-2.29	$551.48M	0.00%
CNTB	$2.36	+7.27%	-2.31	$148.59M	0.00%
CNTX	$0.36	-6.52%	-6.84	$33.47M	0.00%
IFRX	$2.16	+1.41%	-4.16	$318.15M	0.00%
IMA	$5.02	-1.57%	-1.49	$56.62M	0.00%

About KLRS

KLRS is led by CEO Andrew Oxtoby, employs 14 people, headquartered in US, publicly traded since 2020.

KLRS stock trades at $3.92 with a market capitalization of $85.56M. The stock is valued at a price-to-earnings (P/E) ratio of -2.86, price-to-book of 1.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.14 and $11.88, and currently trades 67.0% below its 52-week high.

On profitability, KLRS generates a return on equity (ROE) of -66.60%, return on capital employed of -58.23%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides